Clinical Trials Market in US 2023-2027

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $2,500	148 Pages	TechNavio	October, 2023	INF18250206

Best Price Guarantee
Price	from $2,500
Length	148 Pages
Publisher	TechNavio
Published Date	October, 2023
SKU	INF18250206

Clinical Trials Market In US 2023-2027

The clinical trials market in US is forecasted to grow by USD 5.9 bn during 2022-2027, accelerating at a CAGR of 5.3% during the forecast period. The report on the clinical trials market in US provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by a rise in a number of clinical trials of drugs, the rise in the adoption of artificial intelligence (AI)-based tools for drug delivery, and the growing demand for personalized medicine and targeted therapies.

Technavio's clinical trials market in US is segmented as below:

By Type

Phase III
Phase I
Phase II
Phase IV

By Service Type

Interventional studies
Observational studies
Expanded access studies

By Indication

Oncology
CNS
Autoimmune/Inflammation
Cardiovascular and others

This study identifies the advancement in technology and scientific research as one of the prime reasons driving the clinical trials market in US growth during the next few years. Also, rise in outsourcing of clinical trial process and growing investment in healthcare and pharmaceutical industries will lead to sizable demand in the market.

The report on the clinical trials market in US covers the following areas:

Clinical trials market in US sizing
Clinical trials market in US forecast
Clinical trials market in US industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading clinical trials market in US vendors that include Medpace Holdings Inc., Laboratory Corp. of America Holdings, Sanofi, CTI Clinical Trial and Consulting Inc., ICON plc, Syneos Health Inc., IQVIA Holdings Inc., Charles River Laboratories International Inc., Parexel International Corp., Pfizer Inc., Thermo Fisher Scientific Inc., Caidya, Accell Clinical Research LLC, Clinipace Inc., eResearchTechnology GmbH, Apex Medical Research Inc., WuXi AppTec Co. Ltd., Novartis AG, Novo Nordisk AS, and Eli Lilly and Co.. Also, the clinical trials market in US analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

1 Executive Summary: 1.1 Market overview; Exhibit 01: Executive Summary - Chart on Market Overview; Exhibit 02: Executive Summary - Data Table on Market Overview; Exhibit 03: Executive Summary - Chart on Country Market Characteristics; Exhibit 04: Executive Summary - Chart on Market Segmentation by Type; Exhibit 05: Executive Summary - Chart on Market Segmentation by Service Type; Exhibit 06: Executive Summary - Chart on Market Segmentation by Indication; Exhibit 07: Executive Summary - Chart on Vendor Market Positioning
2 Market Landscape: 2.1 Market ecosystem; Exhibit 08: Parent market; Exhibit 09: Market Characteristics
3 Market Sizing: 3.1 Market definition; Exhibit 10: Offerings of vendors included in the market definition; 3.2 Market segment analysis; Exhibit 11: Market segments; 3.3 Market size 2022; 3.4 Market outlook: Forecast for 2022-2027; Exhibit 12: Chart on US - Market size and forecast 2022-2027 ($ billion); Exhibit 13: Data Table on US - Market size and forecast 2022-2027 ($ billion); Exhibit 14: Chart on US: Year-over-year growth 2022-2027 (%); Exhibit 15: Data Table on US: Year-over-year growth 2022-2027 (%)
4 Historic Market Size: 4.1 Clinical trials market in US 2017 - 2021; Exhibit 16: Historic Market Size - Data Table on clinical trials market in US 2017 - 2021 ($ billion); 4.2 Type Segment Analysis 2017 - 2021; Exhibit 17: Historic Market Size - Type Segment 2017 - 2021 ($ billion); 4.3 Service Type Segment Analysis 2017 - 2021; Exhibit 18: Historic Market Size - Service Type Segment 2017 - 2021 ($ billion); 4.4 Indication Segment Analysis 2017 - 2021; Exhibit 19: Historic Market Size - Indication Segment 2017 - 2021 ($ billion)
5 Five Forces Analysis: 5.1 Five forces summary; Exhibit 20: Five forces analysis - Comparison between 2022 and 2027; 5.2 Bargaining power of buyers; Exhibit 21: Chart on Bargaining power of buyers - Impact of key factors 2022 and 2027; 5.3 Bargaining power of suppliers; Exhibit 22: Bargaining power of suppliers - Impact of key factors in 2022 and 2027; 5.4 Threat of new entrants; Exhibit 23: Threat of new entrants - Impact of key factors in 2022 and 2027; 5.5 Threat of substitutes; Exhibit 24: Threat of substitutes - Impact of key factors in 2022 and 2027; 5.6 Threat of rivalry; Exhibit 25: Threat of rivalry - Impact of key factors in 2022 and 2027; 5.7 Market condition; Exhibit 26: Chart on Market condition - Five forces 2022 and 2027
6 Market Segmentation by Type: 6.1 Market segments; Exhibit 27: Chart on Type - Market share 2022-2027 (%); Exhibit 28: Data Table on Type - Market share 2022-2027 (%); 6.2 Comparison by Type; Exhibit 29: Chart on Comparison by Type; Exhibit 30: Data Table on Comparison by Type; 6.3 Phase III - Market size and forecast 2022-2027; Exhibit 31: Chart on Phase III - Market size and forecast 2022-2027 ($ billion); Exhibit 32: Data Table on Phase III - Market size and forecast 2022-2027 ($ billion); Exhibit 33: Chart on Phase III - Year-over-year growth 2022-2027 (%); Exhibit 34: Data Table on Phase III - Year-over-year growth 2022-2027 (%); 6.4 Phase I - Market size and forecast 2022-2027; Exhibit 35: Chart on Phase I - Market size and forecast 2022-2027 ($ billion); Exhibit 36: Data Table on Phase I - Market size and forecast 2022-2027 ($ billion); Exhibit 37: Chart on Phase I - Year-over-year growth 2022-2027 (%); Exhibit 38: Data Table on Phase I - Year-over-year growth 2022-2027 (%); 6.5 Phase II - Market size and forecast 2022-2027; Exhibit 39: Chart on Phase II - Market size and forecast 2022-2027 ($ billion); Exhibit 40: Data Table on Phase II - Market size and forecast 2022-2027 ($ billion); Exhibit 41: Chart on Phase II - Year-over-year growth 2022-2027 (%); Exhibit 42: Data Table on Phase II - Year-over-year growth 2022-2027 (%); 6.6 Phase IV - Market size and forecast 2022-2027; Exhibit 43: Chart on Phase IV - Market size and forecast 2022-2027 ($ billion); Exhibit 44: Data Table on Phase IV - Market size and forecast 2022-2027 ($ billion); Exhibit 45: Chart on Phase IV - Year-over-year growth 2022-2027 (%); Exhibit 46: Data Table on Phase IV - Year-over-year growth 2022-2027 (%); 6.7 Market opportunity by Type; Exhibit 47: Market opportunity by Type ($ billion); Exhibit 48: Data Table on Market opportunity by Type ($ billion)
7 Market Segmentation by Service Type: 7.1 Market segments; Exhibit 49: Chart on Service Type - Market share 2022-2027 (%); Exhibit 50: Data Table on Service Type - Market share 2022-2027 (%); 7.2 Comparison by Service Type; Exhibit 51: Chart on Comparison by Service Type; Exhibit 52: Data Table on Comparison by Service Type; 7.3 Interventional studies - Market size and forecast 2022-2027; Exhibit 53: Chart on Interventional studies - Market size and forecast 2022-2027 ($ billion); Exhibit 54: Data Table on Interventional studies - Market size and forecast 2022-2027 ($ billion); Exhibit 55: Chart on Interventional studies - Year-over-year growth 2022-2027 (%); Exhibit 56: Data Table on Interventional studies - Year-over-year growth 2022-2027 (%); 7.4 Observational studies - Market size and forecast 2022-2027; Exhibit 57: Chart on Observational studies - Market size and forecast 2022-2027 ($ billion); Exhibit 58: Data Table on Observational studies - Market size and forecast 2022-2027 ($ billion); Exhibit 59: Chart on Observational studies - Year-over-year growth 2022-2027 (%); Exhibit 60: Data Table on Observational studies - Year-over-year growth 2022-2027 (%); 7.5 Expanded access studies - Market size and forecast 2022-2027; Exhibit 61: Chart on Expanded access studies - Market size and forecast 2022-2027 ($ billion); Exhibit 62: Data Table on Expanded access studies - Market size and forecast 2022-2027 ($ billion); Exhibit 63: Chart on Expanded access studies - Year-over-year growth 2022-2027 (%); Exhibit 64: Data Table on Expanded access studies - Year-over-year growth 2022-2027 (%); 7.6 Market opportunity by Service Type; Exhibit 65: Market opportunity by Service Type ($ billion); Exhibit 66: Data Table on Market opportunity by Service Type ($ billion)
8 Market Segmentation by Indication: 8.1 Market segments; Exhibit 67: Chart on Indication - Market share 2022-2027 (%); Exhibit 68: Data Table on Indication - Market share 2022-2027 (%); 8.2 Comparison by Indication; Exhibit 69: Chart on Comparison by Indication; Exhibit 70: Data Table on Comparison by Indication; 8.3 Oncology - Market size and forecast 2022-2027; Exhibit 71: Chart on Oncology - Market size and forecast 2022-2027 ($ billion); Exhibit 72: Data Table on Oncology - Market size and forecast 2022-2027 ($ billion); Exhibit 73: Chart on Oncology - Year-over-year growth 2022-2027 (%); Exhibit 74: Data Table on Oncology - Year-over-year growth 2022-2027 (%); 8.4 CNS - Market size and forecast 2022-2027; Exhibit 75: Chart on CNS - Market size and forecast 2022-2027 ($ billion); Exhibit 76: Data Table on CNS - Market size and forecast 2022-2027 ($ billion); Exhibit 77: Chart on CNS - Year-over-year growth 2022-2027 (%); Exhibit 78: Data Table on CNS - Year-over-year growth 2022-2027 (%); 8.5 Autoimmune/inflammation - Market size and forecast 2022-2027; Exhibit 79: Chart on Autoimmune/inflammation - Market size and forecast 2022-2027 ($ billion); Exhibit 80: Data Table on Autoimmune/inflammation - Market size and forecast 2022-2027 ($ billion); Exhibit 81: Chart on Autoimmune/inflammation - Year-over-year growth 2022-2027 (%); Exhibit 82: Data Table on Autoimmune/inflammation - Year-over-year growth 2022-2027 (%); 8.6 Cardiovascular and others - Market size and forecast 2022-2027; Exhibit 83: Chart on Cardiovascular and others - Market size and forecast 2022-2027 ($ billion); Exhibit 84: Data Table on Cardiovascular and others - Market size and forecast 2022-2027 ($ billion); Exhibit 85: Chart on Cardiovascular and others - Year-over-year growth 2022-2027 (%); Exhibit 86: Data Table on Cardiovascular and others - Year-over-year growth 2022-2027 (%); 8.7 Market opportunity by Indication; Exhibit 87: Market opportunity by Indication ($ billion); Exhibit 88: Data Table on Market opportunity by Indication ($ billion)
9 Customer Landscape: 9.1 Customer landscape overview; Exhibit 89: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
10 Drivers, Challenges, and Trends: 10.1 Market drivers; 10.2 Market challenges; 10.3 Impact of drivers and challenges; Exhibit 90: Impact of drivers and challenges in 2022 and 2027; 10.4 Market trends
11 Vendor Landscape: 11.1 Overview; 11.2 Vendor landscape; Exhibit 91: Overview on Criticality of inputs and Factors of differentiation; 11.3 Landscape disruption; Exhibit 92: Overview on factors of disruption; 11.4 Industry risks; Exhibit 93: Impact of key risks on business
12 Vendor Analysis: 12.1 Vendors covered; Exhibit 94: Vendors covered; 12.2 Market positioning of vendors; Exhibit 95: Matrix on vendor position and classification; 12.3 Accell Clinical Research LLC; Exhibit 96: Accell Clinical Research LLC - Overview; Exhibit 97: Accell Clinical Research LLC - Key offerings; 12.4 Caidya; Exhibit 98: Caidya - Overview; Exhibit 99: Caidya - Key offerings; 12.5 Charles River Laboratories International Inc.; Exhibit 100: Charles River Laboratories International Inc. - Overview; Exhibit 101: Charles River Laboratories International Inc. - Business segments; Exhibit 102: Charles River Laboratories International Inc. - Key news; Exhibit 103: Charles River Laboratories International Inc. - Key offerings; Exhibit 104: Charles River Laboratories International Inc. - Segment focus; 12.6 Clinipace Inc.; Exhibit 105: Clinipace Inc. - Overview; Exhibit 106: Clinipace Inc. - Product / Service; Exhibit 107: Clinipace Inc. - Key offerings; 12.7 CTI Clinical Trial and Consulting Inc.; Exhibit 108: CTI Clinical Trial and Consulting Inc. - Overview; Exhibit 109: CTI Clinical Trial and Consulting Inc. - Product / Service; Exhibit 110: CTI Clinical Trial and Consulting Inc. - Key offerings; 12.8 Eli Lilly and Co.; Exhibit 111: Eli Lilly and Co. - Overview; Exhibit 112: Eli Lilly and Co. - Product / Service; Exhibit 113: Eli Lilly and Co. - Key news; Exhibit 114: Eli Lilly and Co. - Key offerings; 12.9 ICON plc; Exhibit 115: ICON plc - Overview; Exhibit 116: ICON plc - Product / Service; Exhibit 117: ICON plc - Key offerings; 12.10 IQVIA Holdings Inc.; Exhibit 118: IQVIA Holdings Inc. - Overview; Exhibit 119: IQVIA Holdings Inc. - Business segments; Exhibit 120: IQVIA Holdings Inc. - Key news; Exhibit 121: IQVIA Holdings Inc. - Key offerings; Exhibit 122: IQVIA Holdings Inc. - Segment focus; 12.11 Laboratory Corp. of America Holdings; Exhibit 123: Laboratory Corp. of America Holdings - Overview; Exhibit 124: Laboratory Corp. of America Holdings - Business segments; Exhibit 125: Laboratory Corp. of America Holdings - Key news; Exhibit 126: Laboratory Corp. of America Holdings - Key offerings; Exhibit 127: Laboratory Corp. of America Holdings - Segment focus; 12.12 Medpace Holdings Inc.; Exhibit 128: Medpace Holdings Inc. - Overview; Exhibit 129: Medpace Holdings Inc. - Product / Service; Exhibit 130: Medpace Holdings Inc. - Key offerings; 12.13 Parexel International Corp.; Exhibit 131: Parexel International Corp. - Overview; Exhibit 132: Parexel International Corp. - Product / Service; Exhibit 133: Parexel International Corp. - Key news; Exhibit 134: Parexel International Corp. - Key offerings; 12.14 Pfizer Inc.; Exhibit 135: Pfizer Inc. - Overview; Exhibit 136: Pfizer Inc. - Product / Service; Exhibit 137: Pfizer Inc. - Key news; Exhibit 138: Pfizer Inc. - Key offerings; 12.15 Sanofi; Exhibit 139: Sanofi - Overview; Exhibit 140: Sanofi - Business segments; Exhibit 141: Sanofi - Key news; Exhibit 142: Sanofi - Key offerings; Exhibit 143: Sanofi - Segment focus; 12.16 Syneos Health Inc.; Exhibit 144: Syneos Health Inc. - Overview; Exhibit 145: Syneos Health Inc. - Business segments; Exhibit 146: Syneos Health Inc. - Key offerings; Exhibit 147: Syneos Health Inc. - Segment focus; 12.17 Thermo Fisher Scientific Inc.; Exhibit 148: Thermo Fisher Scientific Inc. - Overview; Exhibit 149: Thermo Fisher Scientific Inc. - Business segments; Exhibit 150: Thermo Fisher Scientific Inc. - Key news; Exhibit 151: Thermo Fisher Scientific Inc. - Key offerings; Exhibit 152: Thermo Fisher Scientific Inc. - Segment focus
13 Appendix: 13.1 Scope of the report; 13.2 Inclusions and exclusions checklist; Exhibit 153: Inclusions checklist; Exhibit 154: Exclusions checklist; 13.3 Currency conversion rates for US$; Exhibit 155: Currency conversion rates for US$; 13.4 Research methodology; Exhibit 156: Research methodology; Exhibit 157: Validation techniques employed for market sizing; Exhibit 158: Information sources; 13.5 List of abbreviations; Exhibit 159: List of abbreviations
Exhibits:: Exhibits1: Executive Summary - Chart on Market Overview; Exhibits2: Executive Summary - Data Table on Market Overview; Exhibits3: Executive Summary - Chart on Country Market Characteristics; Exhibits4: Executive Summary - Chart on Market Segmentation by Type; Exhibits5: Executive Summary - Chart on Market Segmentation by Service Type; Exhibits6: Executive Summary - Chart on Market Segmentation by Indication; Exhibits7: Executive Summary - Chart on Vendor Market Positioning; Exhibits8: Parent market; Exhibits9: Market Characteristics; Exhibits10: Offerings of vendors included in the market definition; Exhibits11: Market segments; Exhibits12: Chart on US - Market size and forecast 2022-2027 ($ billion); Exhibits13: Data Table on US - Market size and forecast 2022-2027 ($ billion); Exhibits14: Chart on US: Year-over-year growth 2022-2027 (%); Exhibits15: Data Table on US: Year-over-year growth 2022-2027 (%); Exhibits16: Historic Market Size - Data Table on clinical trials market in US 2017 - 2021 ($ billion); Exhibits17: Historic Market Size - Type Segment 2017 - 2021 ($ billion); Exhibits18: Historic Market Size - Service Type Segment 2017 - 2021 ($ billion); Exhibits19: Historic Market Size - Indication Segment 2017 - 2021 ($ billion); Exhibits20: Five forces analysis - Comparison between 2022 and 2027; Exhibits21: Chart on Bargaining power of buyers - Impact of key factors 2022 and 2027; Exhibits22: Bargaining power of suppliers - Impact of key factors in 2022 and 2027; Exhibits23: Threat of new entrants - Impact of key factors in 2022 and 2027; Exhibits24: Threat of substitutes - Impact of key factors in 2022 and 2027; Exhibits25: Threat of rivalry - Impact of key factors in 2022 and 2027; Exhibits26: Chart on Market condition - Five forces 2022 and 2027; Exhibits27: Chart on Type - Market share 2022-2027 (%); Exhibits28: Data Table on Type - Market share 2022-2027 (%); Exhibits29: Chart on Comparison by Type; Exhibits30: Data Table on Comparison by Type; Exhibits31: Chart on Phase III - Market size and forecast 2022-2027 ($ billion); Exhibits32: Data Table on Phase III - Market size and forecast 2022-2027 ($ billion); Exhibits33: Chart on Phase III - Year-over-year growth 2022-2027 (%); Exhibits34: Data Table on Phase III - Year-over-year growth 2022-2027 (%); Exhibits35: Chart on Phase I - Market size and forecast 2022-2027 ($ billion); Exhibits36: Data Table on Phase I - Market size and forecast 2022-2027 ($ billion); Exhibits37: Chart on Phase I - Year-over-year growth 2022-2027 (%); Exhibits38: Data Table on Phase I - Year-over-year growth 2022-2027 (%); Exhibits39: Chart on Phase II - Market size and forecast 2022-2027 ($ billion); Exhibits40: Data Table on Phase II - Market size and forecast 2022-2027 ($ billion); Exhibits41: Chart on Phase II - Year-over-year growth 2022-2027 (%); Exhibits42: Data Table on Phase II - Year-over-year growth 2022-2027 (%); Exhibits43: Chart on Phase IV - Market size and forecast 2022-2027 ($ billion); Exhibits44: Data Table on Phase IV - Market size and forecast 2022-2027 ($ billion); Exhibits45: Chart on Phase IV - Year-over-year growth 2022-2027 (%); Exhibits46: Data Table on Phase IV - Year-over-year growth 2022-2027 (%); Exhibits47: Market opportunity by Type ($ billion); Exhibits48: Data Table on Market opportunity by Type ($ billion); Exhibits49: Chart on Service Type - Market share 2022-2027 (%); Exhibits50: Data Table on Service Type - Market share 2022-2027 (%); Exhibits51: Chart on Comparison by Service Type; Exhibits52: Data Table on Comparison by Service Type; Exhibits53: Chart on Interventional studies - Market size and forecast 2022-2027 ($ billion); Exhibits54: Data Table on Interventional studies - Market size and forecast 2022-2027 ($ billion); Exhibits55: Chart on Interventional studies - Year-over-year growth 2022-2027 (%); Exhibits56: Data Table on Interventional studies - Year-over-year growth 2022-2027 (%); Exhibits57: Chart on Observational studies - Market size and forecast 2022-2027 ($ billion); Exhibits58: Data Table on Observational studies - Market size and forecast 2022-2027 ($ billion); Exhibits59: Chart on Observational studies - Year-over-year growth 2022-2027 (%); Exhibits60: Data Table on Observational studies - Year-over-year growth 2022-2027 (%); Exhibits61: Chart on Expanded access studies - Market size and forecast 2022-2027 ($ billion); Exhibits62: Data Table on Expanded access studies - Market size and forecast 2022-2027 ($ billion); Exhibits63: Chart on Expanded access studies - Year-over-year growth 2022-2027 (%); Exhibits64: Data Table on Expanded access studies - Year-over-year growth 2022-2027 (%); Exhibits65: Market opportunity by Service Type ($ billion); Exhibits66: Data Table on Market opportunity by Service Type ($ billion); Exhibits67: Chart on Indication - Market share 2022-2027 (%); Exhibits68: Data Table on Indication - Market share 2022-2027 (%); Exhibits69: Chart on Comparison by Indication; Exhibits70: Data Table on Comparison by Indication; Exhibits71: Chart on Oncology - Market size and forecast 2022-2027 ($ billion); Exhibits72: Data Table on Oncology - Market size and forecast 2022-2027 ($ billion); Exhibits73: Chart on Oncology - Year-over-year growth 2022-2027 (%); Exhibits74: Data Table on Oncology - Year-over-year growth 2022-2027 (%); Exhibits75: Chart on CNS - Market size and forecast 2022-2027 ($ billion); Exhibits76: Data Table on CNS - Market size and forecast 2022-2027 ($ billion); Exhibits77: Chart on CNS - Year-over-year growth 2022-2027 (%); Exhibits78: Data Table on CNS - Year-over-year growth 2022-2027 (%); Exhibits79: Chart on Autoimmune/inflammation - Market size and forecast 2022-2027 ($ billion); Exhibits80: Data Table on Autoimmune/inflammation - Market size and forecast 2022-2027 ($ billion); Exhibits81: Chart on Autoimmune/inflammation - Year-over-year growth 2022-2027 (%); Exhibits82: Data Table on Autoimmune/inflammation - Year-over-year growth 2022-2027 (%); Exhibits83: Chart on Cardiovascular and others - Market size and forecast 2022-2027 ($ billion); Exhibits84: Data Table on Cardiovascular and others - Market size and forecast 2022-2027 ($ billion); Exhibits85: Chart on Cardiovascular and others - Year-over-year growth 2022-2027 (%); Exhibits86: Data Table on Cardiovascular and others - Year-over-year growth 2022-2027 (%); Exhibits87: Market opportunity by Indication ($ billion); Exhibits88: Data Table on Market opportunity by Indication ($ billion); Exhibits89: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria; Exhibits90: Impact of drivers and challenges in 2022 and 2027; Exhibits91: Overview on Criticality of inputs and Factors of differentiation; Exhibits92: Overview on factors of disruption; Exhibits93: Impact of key risks on business; Exhibits94: Vendors covered; Exhibits95: Matrix on vendor position and classification; Exhibits96: Accell Clinical Research LLC - Overview; Exhibits97: Accell Clinical Research LLC - Key offerings; Exhibits98: Caidya - Overview; Exhibits99: Caidya - Key offerings; Exhibits100: Charles River Laboratories International Inc. - Overview; Exhibits101: Charles River Laboratories International Inc. - Business segments; Exhibits102: Charles River Laboratories International Inc. - Key news; Exhibits103: Charles River Laboratories International Inc. - Key offerings; Exhibits104: Charles River Laboratories International Inc. - Segment focus; Exhibits105: Clinipace Inc. - Overview; Exhibits106: Clinipace Inc. - Product / Service; Exhibits107: Clinipace Inc. - Key offerings; Exhibits108: CTI Clinical Trial and Consulting Inc. - Overview; Exhibits109: CTI Clinical Trial and Consulting Inc. - Product / Service; Exhibits110: CTI Clinical Trial and Consulting Inc. - Key offerings; Exhibits111: Eli Lilly and Co. - Overview; Exhibits112: Eli Lilly and Co. - Product / Service; Exhibits113: Eli Lilly and Co. - Key news; Exhibits114: Eli Lilly and Co. - Key offerings; Exhibits115: ICON plc - Overview; Exhibits116: ICON plc - Product / Service; Exhibits117: ICON plc - Key offerings; Exhibits118: IQVIA Holdings Inc. - Overview; Exhibits119: IQVIA Holdings Inc. - Business segments; Exhibits120: IQVIA Holdings Inc. - Key news; Exhibits121: IQVIA Holdings Inc. - Key offerings; Exhibits122: IQVIA Holdings Inc. - Segment focus; Exhibits123: Laboratory Corp. of America Holdings - Overview; Exhibits124: Laboratory Corp. of America Holdings - Business segments; Exhibits125: Laboratory Corp. of America Holdings - Key news; Exhibits126: Laboratory Corp. of America Holdings - Key offerings; Exhibits127: Laboratory Corp. of America Holdings - Segment focus; Exhibits128: Medpace Holdings Inc. - Overview; Exhibits129: Medpace Holdings Inc. - Product / Service; Exhibits130: Medpace Holdings Inc. - Key offerings; Exhibits131: Parexel International Corp. - Overview; Exhibits132: Parexel International Corp. - Product / Service; Exhibits133: Parexel International Corp. - Key news; Exhibits134: Parexel International Corp. - Key offerings; Exhibits135: Pfizer Inc. - Overview; Exhibits136: Pfizer Inc. - Product / Service; Exhibits137: Pfizer Inc. - Key news; Exhibits138: Pfizer Inc. - Key offerings; Exhibits139: Sanofi - Overview; Exhibits140: Sanofi - Business segments; Exhibits141: Sanofi - Key news; Exhibits142: Sanofi - Key offerings; Exhibits143: Sanofi - Segment focus; Exhibits144: Syneos Health Inc. - Overview; Exhibits145: Syneos Health Inc. - Business segments; Exhibits146: Syneos Health Inc. - Key offerings; Exhibits147: Syneos Health Inc. - Segment focus; Exhibits148: Thermo Fisher Scientific Inc. - Overview; Exhibits149: Thermo Fisher Scientific Inc. - Business segments; Exhibits150: Thermo Fisher Scientific Inc. - Key news; Exhibits151: Thermo Fisher Scientific Inc. - Key offerings; Exhibits152: Thermo Fisher Scientific Inc. - Segment focus; Exhibits153: Inclusions checklist; Exhibits154: Exclusions checklist; Exhibits155: Currency conversion rates for US$; Exhibits156: Research methodology; Exhibits157: Validation techniques employed for market sizing; Exhibits158: Information sources; Exhibits159: List of abbreviations